MUFG Securities EMEA plc Increases Stock Position in DexCom, Inc. $DXCM

MUFG Securities EMEA plc boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 113.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,989 shares of the medical device company’s stock after buying an additional 8,483 shares during the quarter. MUFG Securities EMEA plc’s holdings in DexCom were worth $1,061,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. AdvisorShares Investments LLC purchased a new position in DexCom during the fourth quarter worth about $481,000. Forsta AP Fonden boosted its stake in DexCom by 157.6% during the fourth quarter. Forsta AP Fonden now owns 255,300 shares of the medical device company’s stock worth $16,944,000 after buying an additional 156,200 shares during the period. Norges Bank purchased a new position in DexCom during the fourth quarter worth about $483,356,000. Eurizon Capital SGR S.p.A. purchased a new position in DexCom during the fourth quarter worth about $3,231,000. Finally, Hillsdale Investment Management Inc. purchased a new position in DexCom during the fourth quarter worth about $883,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of several recent research reports. Mizuho set a $75.00 price objective on shares of DexCom in a research note on Friday, May 1st. TD Cowen lowered their price objective on shares of DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $82.42.

Insider Activity at DexCom

In related news, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the sale, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,871 shares of company stock valued at $2,306,638 over the last 90 days. 0.28% of the stock is owned by corporate insiders.

DexCom Trading Down 1.9%

NASDAQ DXCM opened at $73.45 on Wednesday. The firm has a 50 day simple moving average of $64.32 and a 200-day simple moving average of $66.64. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The firm has a market cap of $28.34 billion, a price-to-earnings ratio of 31.39, a PEG ratio of 1.24 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.32 earnings per share. Equities research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.